Drug Report History
Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.
The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.
Version v2-FR | Version v1-EN | |
---|---|---|
Language | French | English |
Date Updated | 2017-12-06 | 2017-12-06 |
Drug Identification Number | 02185377 | 02185377 |
Brand name | BRETYLIUM TOSYLATE INJECTION USP | BRETYLIUM TOSYLATE INJECTION USP |
Common or Proper name | bretylium | bretylium |
Company Name | SANDOZ CANADA INCORPORATED | SANDOZ CANADA INCORPORATED |
Ingredients | BRETYLIUM TOSYLATE | BRETYLIUM TOSYLATE |
Strength(s) | 50MG | 50MG |
Dosage form(s) | SOLUTION | SOLUTION |
Route of administration | INTRAMUSCULAR INTRAVENOUS | INTRAMUSCULAR INTRAVENOUS |
Packaging size | 5 x 10ML VIALS | 5 x 10ML VIALS |
ATC code | C01BD | C01BD |
ATC description | ANTIARRHYTHMICS, CLASS I AND III | ANTIARRHYTHMICS, CLASS I AND III |
Reason for discontinuation | Manufacturing issues | Manufacturing issues |
Anticipated discontinuation date | ||
Actual discontinuation date | 2017-12-04 | 2017-12-04 |
Remaining supply date | 2017-12-15 | 2017-12-15 |
Discontinuation status | Discontinued | Discontinued |
Discontinuation decision reversal | no | no |
Tier 3 Status | No | No |
Information on remaining supply | ||
Company comments | ||
Health Canada comments |